Endocannabinoid system targeted therapeutics market is projected to be over USD 5 billion by 2030, p
So far, more than 100 different cannabinoids have been identified, and there is a growing body of evidence supporting the clinical benefits of this class of compounds in treating the symptoms of a wide variety of chronic health conditions
Roots Analysis is pleased to announce the publication of its recent study, titled, “Endocannabinoid System Targeted Therapeutics Market, 2020-2030 “
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of endocannabinoid system targeting drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
A detailed assessment of the current market landscape of drug developers engaged in the development of endocannabinoid system targeted therapeutics.
Detailed profiles of developers of endocannabinoid system targeted therapeutics (shortlisted on the basis of the number of development programs).
An in-depth analysis of nearly 600 grants that have been awarded to research institutes engaged in endocannabinoid system targeted therapeutics projects.
An analysis of the partnerships that have been established in this domain, in the recent past.
A detailed analysis of the various mergers and acquisitions that have taken place in this domain, between 2016-2020
An insightful chessboard analysis highlighting the most popular drug development strategies / paths adopted by various drug developers in the domain of endocannabinoid system targeted therapeutics.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Target Disease Indication
Route of Administration
Asia-Pacific and the Rest of the World